lerodalcibep
AssetAlso called HST101, LIB003, Lyrokaul
Inhibits PCSK9, preserving LDL receptors and increasing clearance of LDL cholesterol from blood.
- Stage
- Approved
- Modality
- Protein or enzyme
- Target
- PCSK9
- 17
- Indications
- 12
- Trials
- 2
- Developers
Approved by the FDA on Dec 12, 2025 (BLA761427). FDA
Indications
17Hypercholesterolemia
Approved, FDA
Heterozygous familial hypercholesterolemia
Approved, FDA
Familial hypercholesterolemia
Approved, libtherapeutics.com
14 more
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials12
- Evidence for its targets2
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.